Sun Pharma Lands 483 As GMP Deficiencies Continue to Plague Facility

International Pharmaceutical Regulatory Monitor
A A
Nearly a year after Sun Pharma began implementing a remediation plan to resolve GMP deficiencies at its Halol, India facility, the FDA continues to fault the company for failing to establish and maintain quality controls in a nine-observation Form 483.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor